With the acceleration of the aging process in society, the incidence of Alzheimer's disease (AD) has shown a significant upward trend. Typically, AD exhibits insidious onset, with patients initially experiencing impairment of thinking and memory functions, followed by the development of emotional and behavioral abnormalities, ultimately leading to the loss of self-care ability. The innovative AD treatment drug (Lecanemab) has been approved by the NMPA and has officially entered China. The annual cost of this drug is about 180,000 yuan, which places a heavy burden on families and society. Furthermore, the clinical application of this drug requires grasping the critical golden window period of early stage AD. Therefore, in the path of China's healthy aging, early prevention and diagnosis of AD is particularly crucial.
The prevention and control of AD and other dementias must be moved forward, from primary prevention of identifying and managing controllable risk factors for middle-aged and elderly people who have not yet developed AD pathological changes and clinical symptoms, to secondary prevention of early diagnosis and early intervention based on the preclinical stage or those who have already developed mild cognitive impairment, so as to increase the emphasis on early prevention of AD, thereby avoiding or delaying AD-related pathological changes and reducing the risk of AD (Level I evidence).
|Source: Chinese Medical Association Neurology Branch Cognitive Disorders Committee. "Guidelines for Primary Prevention of Alzheimer's Disease in China". Chinese Medical Journal, Vol. 100, No. 35, September 22, 2020
The importance of early screening and diagnosis of Alzheimer's disease
·AD high-risk factor screening is the key and core of the comprehensive management plan
For people at high risk of AD, suspected of AD, or unable to rule out the possibility of AD, complete and detailed clinical and laboratory examinations are required
The full management plan for confirmed patients should also focus on monitoring the condition or efficacy after starting treatment
|Source: "2023 China Alzheimer's Disease Data and Prevention and Control Strategies"
Yicean assists the whole process comprehensive management for AD with memory testing.
New target UCH-L1
The plasma clinical data for differential diagnosis of AD and healthy people showed that its contribution was higher than that of NfL and Aβ42, and it is a new target with high potential.
High compliance:
Non-invasive blood sample testing leads to higher acceptance and better patient compliance
High practicality
Using a fully automated magnetic microparticle chemiluminescence platform, low cost and high commercialization
High precision
Adopting new technology and exclusive patented technology, pg-level sensitivity is within reach, with more than 1,000 clinical samples verified, and the AUC value of six joint tests is 0.944
1. Physical examination population over 45 years old: early screening, early prevention and clear next management plan
2. People with three highs and cardiovascular and cerebrovascular diseases: People at high risk of AD, testing biomarkers and assessing the risk of disease
3. People with depression, sleep disorders, and sensory system abnormalities: People at high risk of AD, testing biomarkers and assessing the risk of disease
4. People with a history of dementia or a family history of dementia: Regular screening is recommended to indicate the risk of disease early and to prevent it early.
5. People with symptoms of memory loss, speech impairment, and personality mutation: People with suspected early cognitive impairment, early diagnosis, and provide reference
6. People with clinically diagnosed cognitive impairment: assisting clinical diagnosis and treatment monitoring
 |
关注微信公众号
|
|